Research ArticleInfectious Disease

A probiotic yeast-based immunotherapy against Clostridioides difficile infection

See allHide authors and affiliations

Science Translational Medicine  28 Oct 2020:
Vol. 12, Issue 567, eaax4905
DOI: 10.1126/scitranslmed.aax4905

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Targeting antitoxins to the intestine

Neutralizing antibodies against Clostridioides difficile toxins TcdA and TcdB have shown promise in combating intestinal C. difficile infection (CDI), but strategies to target such antibodies to the colon are lacking. Chen et al. generated a stable transfectant of Saccharomyces boulardii expressing neutralizing tetra-specific antibodies against these C. difficile toxins. Oral administration of the modified S. boulardii strain showed efficacy against primary and recurrent infection in prophylactic and therapeutic mouse models of CDI, indicating the potential of the engineered probiotic to treat this intestinal disease.

View Full Text

Stay Connected to Science Translational Medicine